Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study

Bookmark and Share
Published: 10 Dec 2017
Views: 2008
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada

Dr Connors presents, in a press conference at the 2017 ASH annual meeting, data from the phase 3 Echelon-1 study looking at brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine as frontline therapy in patients with previously untreated stage III or IV hodgkin lymphoma.

Read the news story or watch our interview with Dr Connors for more information.